English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

O verexpression of vascular endothelial growth factor (VEGF) appears important in the pathogenesis of retinopathy of prematurity (ROP). Bevacizumab (Avastin; Genentech, Inc, South San Francisco, California) is a recombinant humanized monoclonal IgG1 antibody. It binds to and inhibits the biological activity of human VEGF. It has been estimated that more than 10 000 patients worldwide have been treated with intravitreous bevacizumab. We report results of a study in postmortem eyes with intravitreous bevacizumab treatment for zone 1, stage 2 ROP in an extremely low-birth-weight infant.

Intravitreous Bevacizumab as Anti–Vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity: A Morphologic Study